R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
| العنوان: | R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study |
|---|---|
| المؤلفون: | Ryo Tominaga, Koichiro Minauchi, Yasuo Morishima, Yoshitoyo Kagami, Kazuhito Yamamoto, Michihide Tokuhira, Satoko Morishima, Shigeru Kusumoto, Shigeo Nakamura, Taro Shibata, Kisato Nosaka, Hirokazu Nagai, Shinichiro Yoshida, Kensei Tobinai, Junya Kuroda, Youko Suehiro, Nobuhiko Yamauchi, Michinori Ogura, Yasushi Kubota, Kunihiro Tsukasaki, Kazuyuki Shimada, Dai Maruyama, Noriko Fukuhara, Yoshihiro Yakushijin, Akira Hangaishi, Hideki Tsujimura, Hirofumi Kobayashi, Yasushi Takamatsu, Yoshiko Inoue, Tomomitsu Hotta, Toshiki Uchida, Yoshitaka Imaizumi, Sachiko Suzuki |
| المصدر: | Cancer Science |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Phases of clinical research, Transplantation, Autologous, Gastroenterology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, International Prognostic Index, autologous stem‐cell transplantation, Clinical Research, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Autologous transplantation, Medicine, Cyclophosphamide, induction chemotherapy, Aged, business.industry, diffuse large B‐cell lymphoma, Hematopoietic Stem Cell Transplantation, Induction chemotherapy, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Progression-Free Survival, Transplantation, Regimen, 030104 developmental biology, Oncology, Doxorubicin, Vincristine, 030220 oncology & carcinogenesis, high‐dose chemotherapy, Prednisone, Original Article, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, business, Diffuse large B-cell lymphoma, JCOG‐LSG |
| الوصف: | The efficiency of upfront consolidation with high‐dose chemotherapy/autologous stem‐cell transplantation (HDCT/ASCT) for newly diagnosed high‐risk diffuse large B‐cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in high‐risk DLBCL patients having an age‐adjusted International Prognostic Index (aaIPI) score of 2 or 3. As induction chemotherapy, 6 cycles of R‐CHOP‐14 (arm A) or 3 cycles of R‐CHOP‐14 followed by 3 cycles of CHASER (arm B) were planned, and patients who responded proceeded to HDCT with LEED and ASCT. The primary endpoint was 2‐y progression‐free survival (PFS), and the main secondary endpoints included overall survival, overall response rate, and adverse events (AEs). In total, 71 patients were enrolled. With a median follow‐up of 40.3 mo, 2‐y PFS in arms A and B were 68.6% (95% confidence interval [CI], 50.5%‐81.2%) and 66.7% (95% CI: 48.8%‐79.5%), respectively. Overall survival at 2 y in arms A and B was 74.3% (95% CI: 56.4%‐85.7%) and 83.3% (95% CI: 66.6%‐92.1%). Overall response rates were 82.9% in arm A and 69.4% in arm B. During induction chemotherapy, 45.7% and 75.0% of patients in arms A and B, respectively, had grade ≥ 3 non‐hematologic toxicities. One patient in arm A and 6 in arm B discontinued induction chemotherapy due to AEs. In conclusion, R‐CHOP‐14 showed higher 2‐y PFS and less toxicity compared with R‐CHOP‐14/CHASER in patients with high‐risk DLBCL, suggesting the former to be a more promising induction regimen for further investigations (UMIN‐CTR, UMIN000003823). The efficiency of upfront consolidation with high‐dose chemotherapy/autologous stem‐cell transplantation (HDCT/ASCT) for newly diagnosed high‐risk diffuse large B‐cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in patients with high‐risk DLBCL who had an age‐adjusted International Prognostic Index (aaIPI) score of 2 or 3. R‐CHOP‐14 showed higher 2‐y PFS and less toxicity compared with R‐CHOP‐14/CHASER in patients with high‐risk DLBCL, suggesting the former to be a more promising induction regimen for further investigations. |
| تدمد: | 1349-7006 1347-9032 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7450511a440b266d76864502962b115Test https://doi.org/10.1111/cas.14604Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e7450511a440b266d76864502962b115 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497006 13479032 |
|---|